Scientists make breakthrough on which patients may face dengue virus complications
Researchers have made a breakthrough on why some dengue virus patients develop complications
A breakthrough has been made on why certain dengue virus patients go on to develop life-threatening complications such as vascular leakage and hemorrhaging.
Published in the online journal eLife, the study explained that researchers examined the blood serum samples of patients with dengue infection.
They found that those who went on to develop dengue hemorrhagic fever had significantly higher levels of the protein chymase, which is produced by mast cells.
Senior study author Soman Abraham, professor of pathology, immunology, and molecular genetics and microbiology at Duke Medicine, commented on the findings.
"In addition to revealing a potential new way to diagnose and treat dengue infections, these findings may have much broader applicability for other infectious diseases where vascular leakage is a major pathologic outcome," he said.
It is estimated that as many as 100 million people are infected with dengue each year, with those residing in tropical climes most vulnerable to the condition.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...